Medarex news from FierceBiotech
NewsMedarex shares dented on analysts' skepticism
Investors dented the value of Medarex shares after analysts doused its recent claims concerning its late-stage cancer drug ipilimumab with cold water. BMO Capital Market's Jason Zhang says that Read more...
Medarex shares slide on news of drug app delay
Shares of Medarex slipped seven percent this morning as investors digested Friday's announcement that its application for a new cancer drug will be delayed into 2009. The developer says that the FDA Read more...
Pfizer halts Phase III cancer trial on poor results
Pfizer's big push into cancer drugs has hit a snag. The company announced that it is halting a late-stage trial of tremelimumab for advanced melanoma after researchers concluded it was no more Read more...
ALSO NOTED: Flamel shares buoyed by partnership buzz; Medarex cuts stake in Genmab; Bush offers new stem cell funds; and much m
> Shares of France's Flamel Technologies were buoyed by an analyst's prediction that the company was nearing a late-stage partnering deal. Read more...
Anti-TNF blockbuster garners positive Phase III data
Schering-Plough, Johnson & Johnson and Medarex unveiled positive new data from two late-stage studies of golimumab, an experimental Read more...
BMS misses a beat in cancer comeback
Amid the upbeat tone to yesterday's release of third quarter income at Bristol-Myers Squibb, executives hit a sour note with their announcement that they would probably not seek FDA approval of their Read more...
ALSO NOTED: Genzyme has made best offer for Bioenvision; Pfizer wants investigators to pursue ex-employee; GSK licenses IP; and
> Genzyme says its current bid for all the shares of Bioenvision it doesn't already own is its best and final offer. Read more...
ALSO NOTED: Medarex therapy gains fast track; J&J suspends trial; and much more...> The FDA has put Medarex's MDX-010 skin cancer therapy on the agency's fast track. Report > Johnson & Johnson says that problems experienced by a vendor in distributing drugs for the clinical trials of golimumab for RA will force it to temporarily suspend enrollment in some Phase III studies. J&J says it will resolve the problem quickly. J&J is co-developing the drug with Schering-Plough. … Read more...C&L: Drakeman resigns from Medarex
Medarex CEO Donald Drakeman (photo) resigned his post as the company issued new findings in its investigation of how stock options were granted over the past 10 … Read more...ALSO NOTED: Catalyst prices IPO; Hollis-Eden raises money; and much more...> Catalyst Pharmaceutical Partners has priced its IPO of 3.4 million shares at $6 per share. Report > Hollis-Eden Pharma is raising $26 million from the sale of shares. Report > Medarex and PacMab struck a deal to market … Read more... | Press ReleasesPRESS RELEASE: Genmab Secures Rights to Antibody from Medarex Genmab Secures Rights to Antibody from Medarex COPENHAGEN, September 13 -- Genmab announced today the execution of an asset exchange agreement with Medarex, Inc. Under the terms of the agreement, Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets